Skip to main content
These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only.
These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only.
Nasal – GLP-3 Triple Agonist GLP-1, GIP, Glucagon 40mg

Nasal – GLP-3 Triple Agonist GLP-1, GIP, Glucagon 40mg

$538.00

844 in stock

844 in stock

  • Name:
    GLP-1, GIP, and Glucagon Receptor Triple-Agonist
  • Sequence:
    H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Aib-Lys-NH₂ (with C20 fatty diacid chain conjugation via linker)
  • Molecular Formula:
    C₂₈₉H₄₅₂N₇₂O₈₈
  • Molecular Weight:
    ≈ 6951.48 g/mol
  • CAS Registry Number:
    2381089-83-2

Triple Agonist (GLP-1 / GIP / Glucagon) – COMPREHENSIVE RESEARCH PEPTIDE FOR TRIPLE RECEPTOR AND METABOLIC SIGNALING STUDIES

Scientific Overview of Triple Agonist (GLP-1 / GIP / Glucagon)

Triple Agonist (GLP-1 / GIP / Glucagon) is a synthetic triple-agonist peptide engineered to activate the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon) receptors simultaneously. It is a next-generation incretin-based analog designed for enhanced receptor engagement, stability, and prolonged activity through fatty acid side-chain acylation.

In in-vitro and in-vivo experimental research, Triple Agonist (GLP-1 / GIP / Glucagon) has been evaluated for its multifaceted receptor interactions and signaling dynamics, focusing on:

• Triple Receptor Co-Activation – examination of concurrent GLP-1R, GIPR, and GCGR binding and second-messenger modulation (Coskun et al., 2023)
• Energy and Metabolic Regulation Pathways – study of combined receptor effects on glucose and lipid metabolism in preclinical models (Shao et al., 2023)
• Peptide Engineering and Acylation Design – analysis of molecular modifications enhancing half-life, receptor specificity, and signal amplitude (Willard et al., 2021)

Triple Agonist (GLP-1 / GIP / Glucagon) is utilized in advanced metabolic and endocrinological research as a tool for understanding poly-agonist mechanisms and integrated receptor signaling across metabolic networks.

COAs

COA_Nasal_RET20N1125
COA_Nasal_RET40N1125

*This peptide is intended solely for laboratory research use. It is not approved for human consumption or therapeutic application.

Skip to content